Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus

Journal of Diabetes

Volumn 7, Issue 5, 2015, Pages 729-739

  Su, Benli ^a   Liu, Haixia ^a   Li, Jing ^a   Sunli, Yongjuan ^a   Liu, Ben ^a   Liu, Dandan ^a   Zhang, Ping ^a   Meng, Xiuxiang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Acarbose; Diabetes mellitus type 2; Gut microbiota; Inflammatory cytokines

Indexed keywords

ACARBOSE; BLOOD CLOTTING FACTOR; CYTOKINE; DNA 16S; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTHROMBIN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CCL2 PROTEIN, HUMAN; GLYCOSIDASE INHIBITOR;

ADD ON THERAPY; ADULT; ARTICLE; BACTERIUM IDENTIFICATION; BIFIDOBACTERIACEAE; BIFIDOBACTERIUM LONGUM; BLOOD LEVEL; CHINESE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENTEROCOCCUS FAECALIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; YOUNG ADULT; AGED; BIFIDOBACTERIUM; BLOOD; CHINA; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; TREATMENT OUTCOME;

ACARBOSE; ADULT; AGED; BIFIDOBACTERIUM; CHEMOKINE CCL2; CHINA; CYTOKINES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL MICROBIOME; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84938555730     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12232     Document Type: Article

References (47)

1. Stamler J, Vaccaro O, Neaton JD etal. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16: 434-444.
2. Chiasson JL, Josse RG, Gomis R etal. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA. 2003; 290: 486-494.
3. Hanefeld M, Cagatay M, Petrowitsch T etal. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies. Eur Heart J. 2004; 25: 10-16.
4. Hanefeld M, Chiasson JL, Koehler C etal. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004; 35: 1073-1078.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
6. Holman RR, Haffner SM, McMurray JJ etal. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1463-1476.
7. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014; 105: 141-150.
8. Mandrup-Poulsen T. Type 2 diabetes mellitus: A metabolic autoinflammatory disease. Dermatol Clin. 2013; 31: 495-506.
9. van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: Causes and consequences. Neth J Med. 2013; 71: 174-187.
10. Cruz NG, Sousa LP, Sousa MO etal. The linkage between inflammation and type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013; 99: 85-92.
11. Wang X, Bao W, Liu J etal. Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Care. 2013; 36: 166-175.
12. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Al-Abri S, Al-Lawati J, Al-Maskari M. Analysis of inflammatory mediators in type 2 diabetes patients. Int. J Endocrinol. 2013; 2013: 976810.
13. Yao L, Herlea-Pana O, Heuser-Baker J, Chen Y, Barlic-Dicen J. Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease. J Immunol Res. 2014; 2014: 181450.
14. Mahmoud F, Al-Ozairi E. Inflammatory cytokines and the risk of cardiovascular complications in type 2 diabetes. Dis Markers. 2013; 35: 235-241.
15. Ofstad AP, Gullestad L, Orvik E etal. Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: The prospective Asker and Baerum Cardiovascular Diabetes (ABCD) cohort study. Cardiovasc Diabetol. 2013; 12: 126.
16. Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: A clinical perspective. Arch Immunol Ther Exp (Warsz). 2013; 61: 119-125.
17. Backhed F, Ding H, Wang T etal. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004; 101: 15718-15723.
18. Cani PD, Amar J, Iglesias MA etal. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56: 1761-1772.
19. Creely SJ, McTernan PG, Kusminski CM etal. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E740-747.
20. Manco M. Endotoxin as a missed link among all the metabolic abnormalities in the metabolic syndrome. Atherosclerosis. 2009; 206: 36; author reply 37.
21. Tuohy KM, Rouzaud GC, Bruck WM etal. Modulation of the human gut microflora towards improved health using prebiotics ? assessment of efficacy. Curr Pharm Des. 2005; 11: 75-90.
22. Tzortzis G, Goulas AK, Gee JM etal. A novel galactooligosaccharide mixture increases the bifidobacterial population numbers in a continuous in vitro fermentation system and in the proximal colonic contents of pigs in vivo. J Nutr. 2005; 135: 1726-1731.
23. Meijer K, de Vos P, Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: What relevance for health? Curr Opin Clin Nutr Metab Care. 2010; 13: 715-721.
24. Sauer J, Richter KK, Pool-Zobel BL. Physiological concentrations of butyrate favorably modulate genes of oxidative and metabolic stress in primary human colon cells. J Nutr Biochem. 2007; 18: 736-745.
25. De Vuyst L, Leroy F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifdobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol. 2011; 149: 73-80.
26. Rinttila T, Kassinen A, Malinen E etal. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004; 97: 1166-1177.
27. Kadziola A, Sogaard M, Svensson B etal. Molecular structure of a barley alpha-amylase-inhibitor complex: Implications for starch binding and catalysis. J Mol Biol. 1998; 278: 205-217.
28. Cani PD, Neyrinck AM, Fava F etal. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50: 2374-2383.
29. Kolida S, Saulnier DM, Gibson GR. Gastrointestinal microflora: Probiotics. Adv Appl Microbiol. 2006; 59: 187-219.
30. Velagapudi VR, Hezaveh R, Reigstad CS etal. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010; 51: 1101-1112.
31. Maruhama Y, Nagasaki A, Kanazawa Y etal. Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients. Tohoku J Exp Med. 1980; 132: 453-462.
32. Xiao DWZ, Yang Y, Chen C, Hong M. A study on intestinal flora of patients with diabetes (in Chinese). Zhong Guo Wei Sheng Tai Za Zhi. 2006; 18: 275-276.
33. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-867.
34. Das A, Mukhopadhyay S. The evil axis of obesity, inflammation and type-2 diabetes. Endocr Metab Immune Disord Drug Targets. 2011; 11: 23-31.
35. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115: 1111-1119.
36. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793-1801.
37. Hotamisligil GS, Peraldi P, Budavari A etal. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271: 665-668.
38. Hanefeld M, Schaper F, Koehler C etal. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: The AI(I)DA study. Horm Metab Res. 2009; 41: 132-136.
39. Pickup JC, Chusney GD, Thomas SM etal. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000; 67: 291-300.
40. Arnalich F, Hernanz A, Lopez-Maderuelo D etal. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res. 2000; 32: 407-412.
41. Chacon MR, Fernandez-Real JM, Richart C etal. Monocyte chemoattractant protein-1 in obesity and type 2 diabetes. Insulin sensitivity study. Obesity (Silver Spring). 2007; 15: 664-672.
42. Koistinen HA, Dusserre E, Ebeling P etal. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and type 2 diabetic subjects. Diabetes Metab Res Rev. 2000; 16: 364-369.
43. Rajkumar H, Mahmood N, Kumar M, Varikuti SR, Challa HR, Myakala SP. Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: A randomized, controlled trial. Mediators Inflamm. 2014; 2014: 348959.
44. Martínez I, Wallace G, Zhang C etal. Diet-induced metabolic improvements in a hamster model of hypercholesterolemia are strongly linked to alterations of the gut microbiota. Appl Environ Microbiol. 2009; 75: 4175-4184.
45. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010; 31: 817-844.
46. Mitaka C. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. Clin Chim Acta. 2005; 351: 17-29.
47. Shi H, Kokoeva MV, Inouye K etal. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006; 116: 3015-3025.